Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Risperidone at low dosage is often used as treatment of acute anxiety symptom. However, patients may be either responder or not. Here we hypothesized that the early response to a low dose of risperidone is predictive to risperidone efficiency.

Subjects with acute anxiety symptoms (Hospital anxiety depression scale) and risperidone prescription would be proposed to be enrolled in the study. A check-up is made at D0, then the subjects begin the treatment (0.5mg risperidone). The same check-up is carried out on the following day (D1). The subjects fulfil a last check-up 12 week after the beginning of treatment (W12). During the D1-W12, the psychiatrist may changes the treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Marion Trousselard
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• anxiety (score above 11 at anxiety scale of HADs)

• To have a prescription for 0.5 mg risperidone/day

• To give the consent

• To have a social protection

• To be adult (18-50 years)

Exclusion Criteria:

• Psychiatric antecedents

• any treatment for mental disease (antidepressant, anxiolytics, etc.)

• Ongoing neurological pathologies

• Scheduled surgery

• addiction

• pregancy

• known intolerance to risperidone

• participation to another biomedical study